Exact Mass: 275.16629259999996

Exact Mass Matches: 275.16629259999996

Found 74 metabolites which its exact mass value is equals to given mass value 275.16629259999996, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Physostigmine

(3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate; 2-hydroxybenzoic acid

C15H21N3O2 (275.1633686)


Physostigmine is a white, odorless, microcrystalline powder. Used as a cholinergic (anticholinesterase) agent and as a veterinary medication. (EPA, 1998) Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Physostigmine is a natural product found in Streptomyces griseofuscus, Streptomyces, and other organisms with data available. A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. See also: Physostigmine Salicylate (active moiety of). A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. [PubChem] S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EB - Parasympathomimetics V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors KEIO_ID E007; [MS2] KO008958 KEIO_ID E007

   

Cyclobenzaprine

dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine

C20H21N (275.16739060000003)


Cyclobenzaprine is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. It is structurally similar to Amitriptyline, differing by only one double bond. D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

   

Arginylthreonine

(2S,3R)-2-{[(2S)-2-amino-5-carbamimidamido-1-hydroxypentylidene]amino}-3-hydroxybutanoate

C10H21N5O4 (275.15934660000005)


Arginylthreonine is a dipeptide composed of arginine and threonine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Threonylarginine

(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C10H21N5O4 (275.15934660000005)


Threonylarginine is a dipeptide composed of threonine and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

3-Hydroxyhexanoylcarnitine

3-Hydroxyhexanoylcarnitine

C13H25NO5 (275.173264)


Hydroxyhexanoycarnitine is an acylcarnitine. More specifically, it is an hydroxyhexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Hydroxyhexanoycarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine hydroxyhexanoycarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Hydroxyhexanoycarnitine

3-[(4-hydroxyhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C13H25NO5 (275.173264)


4-Hydroxyhexanoycarnitine is an acylcarnitine. More specifically, it is an 4-hydroxyhexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxyhexanoycarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxyhexanoycarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. 4-Hydroxyhexanoycarnitine is elevated in the urine of individuals with metabolic syndrome (PMID: 33295818). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5R)-5-Hydroxyhexanoylcarnitine

3-[(5-hydroxyhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C13H25NO5 (275.173264)


(5R)-5-hydroxyhexanoylcarnitine is an acylcarnitine. More specifically, it is an (5R)-5-hydroxyhexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5R)-5-hydroxyhexanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5R)-5-hydroxyhexanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. (5R)-5-hydroxyhexanoylcarnitine is elevated in the urine of individuals with metabolic syndrome (PMID: 33295818). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxyprimaquine

8-[(5-aminopentan-2-yl)amino]-6-methoxyquinolin-5-ol

C15H21N3O2 (275.1633686)


   
   

N-((R)-3-Hydroxy-decanoyl)-L-serin|N-((R)-3-hydroxy-decanoyl)-L-serine|Serratamic acid|Serrataminsaeure

N-((R)-3-Hydroxy-decanoyl)-L-serin|N-((R)-3-hydroxy-decanoyl)-L-serine|Serratamic acid|Serrataminsaeure

C13H25NO5 (275.173264)


   
   

Eserine

Physostigmine

C15H21N3O2 (275.1633686)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.444 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.438

   

Physostigmine

NCGC00093889-13_C15H21N3O2_Antilirium

C15H21N3O2 (275.1633686)


CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5547; ORIGINAL_PRECURSOR_SCAN_NO 5545 S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EB - Parasympathomimetics V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5557; ORIGINAL_PRECURSOR_SCAN_NO 5556 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5565; ORIGINAL_PRECURSOR_SCAN_NO 5563 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5582; ORIGINAL_PRECURSOR_SCAN_NO 5581 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5563; ORIGINAL_PRECURSOR_SCAN_NO 5562 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5574; ORIGINAL_PRECURSOR_SCAN_NO 5571 Formula(Parent): C15H21N3O2; Bottle Name:Eserine; PRIME Parent Name:Eserine / Physostigmine; PRIME in-house No.:V0352 0226; SubCategory_DNP: Alkaloids derived from tryptophan, Simple tryptamine alkaloids, Indole alkaloids Annotation level-1

   

N-Acetyl-5-hydroxytryptamine

N-Acetyl-5-hydroxytryptamine

C15H21N3O2 (275.1633686)


   

4-(5H-Dibenzo[a.d]cycloheptan-5-ylidene)piperidin

4-(5H-Dibenzo[a.d]cycloheptan-5-ylidene)piperidin

C20H21N (275.16739060000003)


   
   

N-(3S-hydroxydecanoyl)-L-serine

N-(3S-hydroxydecanoyl)-L-serine

C13H25NO5 (275.173264)


   

Arg-THR

2-(2-amino-3-hydroxybutanamido)-5-carbamimidamidopentanoic acid

C10H21N5O4 (275.15934660000005)


   

THR-Arg

2-(2-amino-5-carbamimidamidopentanamido)-3-hydroxybutanoic acid

C10H21N5O4 (275.15934660000005)


A dipeptide formed from L-threonine and L-arginine residues.

   

Serratamic acid

N-(3S-hydroxydecanoyl)-L-serine

C13H25NO5 (275.173264)


   

CAR 6:0;O

(3S)-3-[(3-hydroxyhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C13H25NO5 (275.173264)


   

4-Decylphenyl isothiocyanate

4-Decylphenyl isothiocyanate

C17H25NS (275.170761)


   

tert-butyl 3-[(dimethylamino)methyl]pyrrolo[2,3-b]pyridine-1-carboxylate

tert-butyl 3-[(dimethylamino)methyl]pyrrolo[2,3-b]pyridine-1-carboxylate

C15H21N3O2 (275.1633686)


   
   

5-(dibutylamino)-2-nitrobenzonitrile

5-(dibutylamino)-2-nitrobenzonitrile

C15H21N3O2 (275.1633686)


   

4-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3,4-DIHYDRO-2H-1,4-BENZOXAZINE

4-METHYL-7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3,4-DIHYDRO-2H-1,4-BENZOXAZINE

C15H22BNO3 (275.16926520000004)


   

2-(cyclopropylmethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2-(cyclopropylmethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

C15H22BNO3 (275.16926520000004)


   

3-(N,N-Dimethylaminocarbonyl)phenylboronic acid pinacol ester

3-(N,N-Dimethylaminocarbonyl)phenylboronic acid pinacol ester

C15H22BNO3 (275.16926520000004)


   

N-(4-tert-Butylphenyl)-2-naphthylamine

N-(4-tert-Butylphenyl)-2-naphthylamine

C20H21N (275.16739060000003)


   

isopropyl 4-(5-amino-1-methyl-1H-benzo[d]imidazol-2-yl)butanoate

isopropyl 4-(5-amino-1-methyl-1H-benzo[d]imidazol-2-yl)butanoate

C15H21N3O2 (275.1633686)


   

tert-butyl (3S)-4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate

tert-butyl (3S)-4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate

C13H25NO5 (275.173264)


   
   

N-METHYL-2-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETAMIDE

N-METHYL-2-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETAMIDE

C15H22BNO3 (275.16926520000004)


   

2-CYCLOBUTOXY-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDINE

2-CYCLOBUTOXY-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDINE

C15H22BNO3 (275.16926520000004)


   

Boc-O-tert-butyl-L-threonine

Boc-O-tert-butyl-L-threonine

C13H25NO5 (275.173264)


   

1,1-dimethyl-2-(4-methoxyphenyl)ethylamine hydrochloride

1,1-dimethyl-2-(4-methoxyphenyl)ethylamine hydrochloride

C15H21N3O2 (275.1633686)


   

N,N-Dimethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N,N-Dimethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

C15H22BNO3 (275.16926520000004)


   

6-Cyclopropylmethoxypyridine-3-boronic acid pinacol ester

6-Cyclopropylmethoxypyridine-3-boronic acid pinacol ester

C15H22BNO3 (275.16926520000004)


   

4-(N,N-Dimethylaminocarbonyl)phenylboronic acid, pinacol ester

4-(N,N-Dimethylaminocarbonyl)phenylboronic acid, pinacol ester

C15H22BNO3 (275.16926520000004)


   

1-(3,5-dimethylphenyl)-7-(1-methylethyl)-Isoquinoline

1-(3,5-dimethylphenyl)-7-(1-methylethyl)-Isoquinoline

C20H21N (275.16739060000003)


   

2-Methyl-2-propanyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-homoserinate

2-Methyl-2-propanyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-homoserinate

C13H25NO5 (275.173264)


   

N-Methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

N-Methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

C15H22BNO3 (275.16926520000004)


   

Boc-D-Thr(tBu)-OH

Boc-D-Thr(tBu)-OH

C13H25NO5 (275.173264)


   

1-[4-(dimethylamino)phenyl]-6-phenylhexatriene

1-[4-(dimethylamino)phenyl]-6-phenylhexatriene

C20H21N (275.16739060000003)


   

benzyl N-(1-pyrrolidin-3-ylazetidin-3-yl)carbamate

benzyl N-(1-pyrrolidin-3-ylazetidin-3-yl)carbamate

C15H21N3O2 (275.1633686)


   

benzyl 3-(3-aminoazetidin-1-yl)pyrrolidine-1-carboxylate

benzyl 3-(3-aminoazetidin-1-yl)pyrrolidine-1-carboxylate

C15H21N3O2 (275.1633686)


   

3-Hydroxyhexanoylcarnitine

3-Hydroxyhexanoylcarnitine

C13H25NO5 (275.173264)


Hydroxyhexanoycarnitine is an acylcarnitine. More specifically, it is an hydroxyhexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Hydroxyhexanoycarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine hydroxyhexanoycarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

3-Hydroxyhexanoyl-L-carnitine

3-Hydroxyhexanoyl-L-carnitine

C13H25NO5 (275.173264)


   

4-Hydroxyhexanoycarnitine

4-Hydroxyhexanoycarnitine

C13H25NO5 (275.173264)


   

(5R)-5-Hydroxyhexanoylcarnitine

(5R)-5-Hydroxyhexanoylcarnitine

C13H25NO5 (275.173264)


   

N-methylcarbamic acid [(8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] ester

N-methylcarbamic acid [(8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] ester

C15H21N3O2 (275.1633686)


   

1-(4-Butylbenzyl)Isoquinoline

1-(4-Butylbenzyl)Isoquinoline

C20H21N (275.16739060000003)


   

1-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-2-indolecarboxamide

1-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-2-indolecarboxamide

C15H21N3O2 (275.1633686)


   

3-ethyl-N-(2H-tetrazol-5-yl)-1-adamantanecarboxamide

3-ethyl-N-(2H-tetrazol-5-yl)-1-adamantanecarboxamide

C14H21N5O (275.1746016)


   
   
   

(1R,2aR,8bR)-1-(hydroxymethyl)-N-propan-2-yl-2a,3,4,8b-tetrahydro-1H-azeto[2,3-c]quinoline-2-carboxamide

(1R,2aR,8bR)-1-(hydroxymethyl)-N-propan-2-yl-2a,3,4,8b-tetrahydro-1H-azeto[2,3-c]quinoline-2-carboxamide

C15H21N3O2 (275.1633686)


   

(1S,2aR,8bR)-1-(hydroxymethyl)-N-propan-2-yl-2a,3,4,8b-tetrahydro-1H-azeto[2,3-c]quinoline-2-carboxamide

(1S,2aR,8bR)-1-(hydroxymethyl)-N-propan-2-yl-2a,3,4,8b-tetrahydro-1H-azeto[2,3-c]quinoline-2-carboxamide

C15H21N3O2 (275.1633686)


   

2-(3-benzyl-2-oxoimidazolidin-1-yl)-N-propylacetamide

2-(3-benzyl-2-oxoimidazolidin-1-yl)-N-propylacetamide

C15H21N3O2 (275.1633686)


   

4-acetamido-N-(2-aminocyclohexyl)benzamide

4-acetamido-N-(2-aminocyclohexyl)benzamide

C15H21N3O2 (275.1633686)


   

cyclobenzaprine

cyclobenzaprine

C20H21N (275.16739060000003)


D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

   
   

1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate

1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate

C15H21N3O2 (275.1633686)


   

Hydroxyhexanoycarnitine

Hydroxyhexanoycarnitine

C13H25NO5 (275.173264)


   

O-hydroxyhexanoyl-L-carnitine

O-hydroxyhexanoyl-L-carnitine

C13H25NO5 (275.173264)


An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexanoyl group as the acyl substituent in which the position of the hydroxy group is unspecified.

   
   
   
   

1-({1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl}oxy)-n-methylmethanimidic acid

1-({1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl}oxy)-n-methylmethanimidic acid

C15H21N3O2 (275.1633686)


   

1-{[(3as,8ar)-1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl]oxy}-n-methylmethanimidic acid

1-{[(3as,8ar)-1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl]oxy}-n-methylmethanimidic acid

C15H21N3O2 (275.1633686)


   

(2s)-2-{[(3r)-1,3-dihydroxydecylidene]amino}-3-hydroxypropanoic acid

(2s)-2-{[(3r)-1,3-dihydroxydecylidene]amino}-3-hydroxypropanoic acid

C13H25NO5 (275.173264)